Meglumine antimoniate-induced pancreatitis.
Torrús
D
D
Massa
B
B
Boix
V
V
Portilla
J
J
Pérez-Mateo
M
M
D017088:AIDS-Related Opportunistic Infections / Q000276:immunology; D000208:Acute Disease; D000328:Adult; D000965:Antimony; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000276:immunology; D008536:Meglumine / Q000009:adverse effects* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced*
D000981:Antiprotozoal Agents; D007166:Immunosuppressive Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony